Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond

@article{Serebruany2013DyspneaAR,
  title={Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond},
  author={Victor L Serebruany and Dirk Sibbing and James J. DiNicolantonio},
  journal={Cardiology},
  year={2013},
  volume={127},
  pages={20 - 24}
}
Context: Oral reversible platelet P2Y12 receptor inhibitors (ticagrelor and elinogrel) cause double-digit rates of dyspnea, while irreversible oral antiplatelet drugs (aspirin, ticlopidoine, clopidogrel, and prasugrel) or intravenous glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban) do not increase the incidence of dyspnea in randomized trials. Dyspnea after oral reversible antiplatelet agents remains unexplained. A transfusion-related acute lung injury (TRALI) hypothesis… 

Tables from this paper

Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes
TLDR
Ticagrelor represents a cost-effective alternative in the spectrum of P2Y12 inhibitors; however, further studies are required to enable the physician to choose the most appropriate antiplatelet agent for each patient.
Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data
TLDR
Cangrelor in percutaneous coronary intervention did not show superiority to the standard antiplatelet therapy, and its future use in this setting still needs to be better assessed.
Reversal of Ticagrelor-Induced Arrhythmias and Cheyne–Stokes Respiration With Aminophylline Infusion
TLDR
A case of incessant Cheyne–Stokes respiration associated with heart rate instability in patient with congestive heart failure and non–ST-segment elevation myocardial infarction is presented, supporting the use of aminophylline as a potential reversal agent of ticagrelor-related AEs.
Real-world incidence of patient-reported dyspnoea with ticagrelor
TLDR
As ticagrelor is widely prescribed as a first-line antiplatelet agent for a range of patients with acute coronary syndrome, the incidence of dyspnoea in a generalized patient cohort may result in higher rates of drug discontinuation, which could lead toHigher rates of rehospitalisation and potential treatment failure than that reported from the controlled setting of a clinical trial.
Dyspnea in Post Percutaneous Transluminal Coronary Angioplasty (PTCA)Patients on Dual Antiplatelets in a Tertiary Care Hospital in South India
TLDR
Risk for dyspnoea induced by Ticagrelor was found to be higher than with Clopidogrel in the same ethnic groups when used as dual antiplatelet along with Aspirin, so it may not be a class effect or due to P2Y12 receptor inhibitory action alone.
Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor
TLDR
It is pointed out that constitutive P2Y12-R signaling is a normal feature of the receptor that might be essential for platelets to respond faster to a vessel injury, and suggested that the beneficial advantages of antiplatelet drugs might be more related to inverse agonism at P2y12- R than to antagonism of ADP-mediated signaling.
Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines
TLDR
A statistically significant decrease in clopidogrel use after the publication of the OCLA study and a significant increase in the trend of esomeprazole is found and the financial impact of different implementation guidelines is estimated.
Investigation of the role of platelet turnover on platelet inhibition and thrombus formation with regard to antiplatelet therapy
TLDR
During anti-platelet therapy platelet turnover may lead to the emergence of a minority of uninhibited platelets sufficient to initiate and drive platelet aggregate formation.
...
1
2
...

References

SHOWING 1-10 OF 36 REFERENCES
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.
TLDR
Despite expected benefit for better bleeding control, further development of reversible antithrombins is severely limited due to the existence of a potentially universal serious adverse event, such as TRALI-syndrome with dyspnea as a predominant clinical manifestation.
Dyspnoea after antiplatelet agents: the AZD6140 controversy
TLDR
Dyspnoea is a very rare complication of the presently approved platelet inhibitors, mostly caused by underlying disease, rather than antiplatelet therapy per se, and plausible mechanisms exist and despite these plausible mechanisms, the true cause of dysPNoea in exposed individuals is unknown.
Ticagrelor: a review of its use in the management of acute coronary syndromes.
TLDR
Clinical data currently available indicate that ticagrelor is a promising option for the treatment of patients with ACS and may be of particular use in those at high risk of ischaemic events or unresponsive to clopidogrel.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
TLDR
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
Platelet inhibition with cangrelor in patients undergoing PCI.
TLDR
Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
TLDR
Among patients who discontinue thienopyridine therapy prior to cardiac surgery, the use of cangrelor compared with placebo resulted in a higher rate of maintenance of platelet inhibition.
Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting.
TLDR
These data closely match the frequency of dyspnea that was observed in the CAPRIE trial, suggesting that therapy with clopidogrel, and/or aspirin holds very small (if any) risk for Dyspnea.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
TLDR
Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding.
Intravenous platelet blockade with cangrelor during PCI.
TLDR
The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point, and the prespecified secondary end points of stent thrombosis and death were lower in the cang Relor group, with no significant increase in the rate of transfusion.
Cangrelor: a review on its mechanism of action and clinical development
TLDR
An overview of the current status of knowledge on cangrelor is provided, focusing on its pharmacologic properties, clinical development and potential future applications.
...
1
2
3
4
...